Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.
The company released stellar a Q3 with the following highlights:
- Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
- Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
- Record 9 months revenues at $10.2 million , up 94%
But wait, there’s more…
The company announced that Hesperco™ Is Now Available At Loblaws, Hesperidin Covid-19 Clinical Trial Results Submitted For Publication.
- Approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw’s banners including:
- Loblaws
- Dominion,
- Zehrs,
- Fortinio’s,
- Your Independent Grocer and Superstore
Steve Saviuk , CEO commented,
We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications. We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.”
But wait, there’s more…
Now sit back, relax and watch this powerful interview with Valeo Pharma.
